Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Nuvectis Pharma, Inc. (NVCT) had Consolidated Net Income/Loss of $-5.33M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-5.33M |
|
-- |
|
-- |
|
$5.57M |
|
$-5.57M |
|
$0.24M |
|
$-5.33M |
|
$-5.33M |
|
$-5.33M |
|
$-5.33M |
|
|
Consolidated Net Income/Loss |
$-5.33M |
$-5.33M |
|
$-5.57M |
|
$-5.57M |
|
19.94M |
|
19.94M |
|
$-0.27 |
|
$-0.27 |
|
| Balance Sheet Financials | |
$30.15M |
|
-- |
|
-- |
|
$30.15M |
|
$9.19M |
|
-- |
|
-- |
|
$9.19M |
|
$20.95M |
|
$20.95M |
|
$20.95M |
|
23.64M |
|
| Cash Flow Statement Financials | |
$-4.17M |
|
-- |
|
$15.51M |
|
$18.53M |
|
$29.86M |
|
$11.33M |
|
$1.37M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.28 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-4.17M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-25.45% |
|
-25.45% |
|
-17.69% |
|
-25.45% |
|
$0.89 |
|
$-0.21 |
|
$-0.21 |
|